Cantor Fitzgerald Comments on Disc Medicine FY2025 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for Disc Medicine in a research report issued on Wednesday, March 5th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($4.59) for the year, up from their previous estimate of ($5.24). The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.08.

A number of other brokerages have also recently weighed in on IRON. Stifel Nicolaus lifted their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Scotiabank lifted their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday. HC Wainwright restated a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a report on Tuesday, January 21st. Wedbush restated an “outperform” rating and issued a $90.00 price objective (up previously from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Finally, TD Cowen began coverage on shares of Disc Medicine in a report on Thursday, February 27th. They issued a “buy” rating for the company. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $89.10.

Disc Medicine Price Performance

Shares of IRON opened at $55.50 on Friday. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $68.86. The stock has a market cap of $1.65 billion, a PE ratio of -13.94 and a beta of 0.73. The firm has a 50-day simple moving average of $57.33 and a two-hundred day simple moving average of $55.75.

Institutional Trading of Disc Medicine

Several institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC raised its position in Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after purchasing an additional 503 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Disc Medicine in the 4th quarter valued at $40,000. Tower Research Capital LLC TRC raised its position in Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after purchasing an additional 266 shares during the last quarter. Quest Partners LLC purchased a new stake in Disc Medicine in the 3rd quarter valued at $131,000. Finally, Quantbot Technologies LP purchased a new stake in Disc Medicine in the 3rd quarter valued at $146,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Insider Buying and Selling

In other news, insider Pamela Stephenson sold 3,137 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $171,217.46. Following the completion of the sale, the insider now owns 69,529 shares in the company, valued at approximately $3,794,892.82. The trade was a 4.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John D. Quisel sold 12,791 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $66.01, for a total transaction of $844,333.91. Following the sale, the chief executive officer now owns 72,065 shares of the company’s stock, valued at $4,757,010.65. This represents a 15.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,080 shares of company stock worth $4,523,520 over the last 90 days. 4.24% of the stock is owned by insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.